Bajaj Healthcare's shares fell 1.10% to ₹336 after the company disclosed a standalone net loss of ₹22.85 crore for the fourth quarter of FY26, contrasting with a net profit of ₹11.17 crore in Q4 FY25. Revenue from operations dipped 0.91% year-on-year, totaling ₹153.05 crore. The company reported a pre-tax loss of ₹20.80 crore, compared to a profit before tax of ₹11.72 crore in the previous year. Despite these setbacks, the EBITDA margin improved to 16.7% from 16.4% a year prior. Segment-wise, domestic API revenue fell by 2.56% to ₹86.85 crore, while API exports decreased by 5.42% to ₹38.54 crore. However, the formulations business saw a significant increase of 27.67%, reaching ₹27.67 crore. The company is progressing with its anti-epileptic molecule, Cenobamate, which is set to launch in Q2 FY27. Additionally, Bajaj Healthcare filed 41 Drug Master Files (DMFs) during the quarter, enhancing its global regulatory presence. The company also converted 2.08 million warrants into equity shares, raising ₹52.7 crore to bolster its balance sheet. Anil Jain, Managing Director, highlighted the challenges faced due to price erosion in domestic APIs and geopolitical disruptions but noted a 19% growth in profit after tax from continuing operations. The board has recommended a final dividend of 30%, translating to ₹1.50 per share for FY26.